TLR7
ENSG00000196664
Target class
Membrane receptor
Chromosome
X
Approved drugs
2
Clinical candidates (approved and in development)
11
- Approved drugs
- 2
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 11
- Chemical probe available
- Yes
- Target name
- TLR7
- Gene name
- Toll like receptor 7
- Gene symbol
- TLR7
- Protein name
- Toll-like receptor 7
- Gene biotype
- Protein coding
- Gene family
- Toll like receptors
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 5
- Highest tissue expression
- 40.52
- Tissue specificity (Gini)
- 0.794
- Tissue specificity (tau)
- 0.99
- KEGG gene identifiers
- hsa:51284
- Protein interaction confidence
- 0.817355
- Protein interaction partners
- 62
- R-HSA-1679131
- R-HSA-168181
- R-HSA-5686938
- R-HSA-9679191
- R-HSA-9692916
- R-HSA-9705671
- R-HSA-975110
- R-HSA-975138
- R-HSA-975155
- R-HSA-9824856
- R-HSA-9833110
- End position
- 12890361
- Start position
- 12867072
- Chromosome
- X
- Strand
- Forward
- Endoplasmic reticulum membrane
- Single-pass type I membrane protein . Endosome . Lysosome . Cytoplasmic vesicle, phagosome . Note=Relocalizes from endoplasmic reticulum to endosome and lysosome upon stimulation with agonist. .
- Tissue specificity (tau)
- 0.989565
- Expression inequality (Gini)
- 0.794372
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 40.52
- Spleen
- 2.28
- Brain - Spinal cord (cervical c-1)
- 2.13
- Small Intestine - Terminal Ileum
- 1.25
- Brain - Substantia nigra
- 1.21
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes40.52
- Spleen2.28
- Brain - Spinal cord (cervical c-1)2.13
- Small Intestine - Terminal Ileum1.25
- Brain - Substantia nigra1.21
- Whole Blood0.92
- Lung0.85
- Nerve - Tibial0.71
- Brain - Hypothalamus0.66
- Adipose - Subcutaneous0.62
- Artery - Aorta0.6
- Artery - Coronary0.57
- Minor Salivary Gland0.55
- Adrenal Gland0.51
- Brain - Amygdala0.51
- Brain - Caudate (basal ganglia)0.51
- Brain - Hippocampus0.49
- Prostate0.47
- Kidney - Medulla0.47
- Colon - Transverse0.45
- Adipose - Visceral (Omentum)0.44
- Artery - Tibial0.41
- Brain - Nucleus accumbens (basal ganglia)0.41
- Brain - Putamen (basal ganglia)0.35
- Cervix - Endocervix0.33
And 29 more, listed on the interactive page.
- GO:0007249
- GO:0032722
- GO:0032727
- GO:0032728
- GO:0032729
- GO:0032757
- GO:0034154
- GO:0043123
- GO:0045087
- GO:0050729
- GO:0051607
- GO:0070305
- GO:0071260
- GO:0000139
- GO:0005737
- GO:0005765
- GO:0005789
- GO:0005886
- GO:0010008
- GO:0036020
- GO:0043235
- GO:0003725
- GO:0003727
- GO:0005515
- GO:0038187
Related records
Trials (687)
- #StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19
- 1-Year Follow up to the 1473-IMIQ Study
- A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting Conditions
- A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses
- A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum
- A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine Candidate
- A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV
- A Cohort Study of Hyperthermia and Imiquimod for the Treatment of Flat Warts
- A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh
- A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects
- A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453
- A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus
- A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
- A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
- A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy
- A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma
- A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base
- A Preventive Treatment for Migrant Workers at High-risk of COVID-19
- A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)
- A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients
Drugs (12)
- Afimetoran Toll-like receptor 7 inhibitor
- AZD-8848 Toll-like receptor 7 agonist
- Bazlitoran Toll-like receptor 7 antagonist
- CPG-52852 Toll-like receptor 7 agonist
- Enpatoran Toll-like receptor 7 antagonist
- GSK-2245035 Toll-like receptor 7 agonist
- Hydroxychloroquine Toll-like receptor 7 antagonist
- Hydroxychloroquine sulfate Toll-like receptor 7 antagonist
- Imiquimod Toll-like receptor 7 agonist
- Resiquimod Toll-like receptor 7 agonist
- Telratolimod Toll-like receptor 7 agonist
- Vesatolimod Toll-like receptor 7 activator